echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Yang Liang, Vice President of Luye Pharma Investment: The Group will usher in a critical turning point

    Yang Liang, Vice President of Luye Pharma Investment: The Group will usher in a critical turning point

    • Last Update: 2022-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Luye Pharma’s self-developed innovative anti-tumor preparation, Goserelin Acetate Sustained-Release Microspheres for Injection (LY01005), has been accepted for marketing in China in the treatment of prostate cancer, and it is expected to become the only goserelin in the world.


    As the first echelon of leading innovative pharmaceutical companies, Luye Pharma joined 15 other innovative pharmaceutical companies in the listed company roadshow session of the 6th China Pharmaceutical Innovation and Investment Conference this year, attracting many experts, scholars and investment elites


    Yang Liang, Vice President of Investor Relations and Public Relations of Luye Pharma, focused on Luye Pharma's global development strategy, innovative drug R&D progress, product market situation, and detailed the progress of key pipelines, global business system in his communication with investors.


    Yang Liang, Vice President of Investor Relations and Public Relations, Luye Pharma

    Yang Liang said that the current Luye Pharma is at a critical turning point


    It is reported that Luye Pharma’s international business operation system has expanded to more than 80 countries and regions around the world, with more than 30 marketed products covering the central nervous system, anti-tumor, cardiovascular and other fields, and business covering major global pharmaceuticals in China, the United States, Europe, and Japan.


    Yang Liang said that Luye Pharma adheres to the strategy of "innovation" and "internationalization", and has been accelerating the clinical and launch progress of key research projects, and systematically building an international business system


    Relying on the advantages of the world's leading microsphere technology platform, Luye Pharma is deeply involved in major diseases such as oncology and central nervous system.


    Also, in the past year


    Yang Liang said that various complex factors such as the international environment, economic cycle, industrial structure and the spread of the epidemic are intertwined, making the future prospects face huge uncertainties


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.